Researchers at Columbia University Fertility Center have achieved a pioneering success in fertility treatment by utilising an AI-guided method for sperm recovery in men with azoospermia. This condition, where ejaculate contains minimal or no sperm, affects 10-15% of men with infertility issues, contributing to around 40% of infertility cases in couples.
The study, documented in a research letter in The Lancet, showcases the first successful pregnancy using this cutting-edge technique. Zev Williams, the senior author and Director of the Columbia University Fertility Center, highlighted the challenges couples face when male-factor infertility leads to bleak prospects for having a biological child. A semen sample may appear normal, yet microscopic examination often reveals only cellular debris without visible sperm.
Traditional surgical sperm extraction methods for azoospermia are frequently unsuccessful and pose risks such as vascular complications, inflammation, and temporary testosterone reduction. Manual inspection of semen samples, performed in a few specialised labs, is an expensive and time-consuming process that risks damaging sperm.
The newly developed STAR (Sperm Tracking and Recovery) method, spearheaded by Williams and his team, integrates advanced imaging, microfluidics, and reproductive endocrinology. It employs sophisticated imaging technology to capture over 8 million images in under an hour. AI identifies sperm cells, while a microfluidic chip isolates the sperm-containing portion of the sample. A robotic system then extracts the sperm cell for embryo creation or storage.
The inaugural application of STAR involved a patient who had been attempting to conceive for nearly two decades, undergoing multiple IVF cycles and sperm retrieval procedures. The method successfully identified two viable sperm cells from a 3.5 mL semen sample, leading to the creation of embryos and a subsequent pregnancy.
Although based on a single case, these findings demonstrate the potential of this technology to overcome significant barriers in treating azoospermia. Larger clinical studies are in progress to further assess STAR’s efficacy across diverse patient groups, offering renewed possibilities for those affected by this condition.
